Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 1 clinical study titled A Phase 1, Randomized, Double-blind, Placebo-controlled, Integrated Single Ascending Dose, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma. The study aims to assess the safety and tolerability of AMG 691, a new drug, in both healthy individuals and those with mild-to-moderate asthma, highlighting its potential significance in respiratory treatment.
The intervention being tested is AMG 691, administered via subcutaneous injection. It is designed to evaluate its effects compared to a placebo in different participant groups, including healthy individuals and those with asthma.
This interventional study is randomized and sequential, with a double-blind design to ensure unbiased results. The primary purpose is treatment-focused, aiming to gather essential data on AMG 691’s safety and efficacy.
The study began on October 16, 2024, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 24, 2025, indicating ongoing progress in the study.
The update on this study could influence Amgen’s stock performance positively, as successful results may enhance investor confidence and market position in the respiratory treatment sector. Competitors in the pharmaceutical industry will be closely monitoring these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.